bluebird bio (BLUE) announced it is implementing a restructuring intended to optimize cost structure and enable quarterly cash flow break-even in the second half of 2025. The initiative includes a reduction in the workforce of approximately 25%.
As part of the restructuring, bluebird plans to sharpen focus on the ongoing commercial launches of LYFGENIA, ZYNTEGLO and SKYSONA to enable continued launch acceleration while it evaluates opportunities to increase its cash resources. The restructuring is projected to result in a 20% reduction in cash operating expenses when fully realized in third quarter, 2025, compared to the prior reporting period.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.